HRP20221269T1 - Pripravci za liječenje mijelofibroze - Google Patents
Pripravci za liječenje mijelofibroze Download PDFInfo
- Publication number
- HRP20221269T1 HRP20221269T1 HRP20221269TT HRP20221269T HRP20221269T1 HR P20221269 T1 HRP20221269 T1 HR P20221269T1 HR P20221269T T HRP20221269T T HR P20221269TT HR P20221269 T HRP20221269 T HR P20221269T HR P20221269 T1 HRP20221269 T1 HR P20221269T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- ylethoxy
- pyrrolidin
- tert
- phenyl
- Prior art date
Links
- 206010028537 myelofibrosis Diseases 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims 10
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 5
- QAFZLTVOFJHYDF-UHFFFAOYSA-N n-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide;hydrate;dihydrochloride Chemical compound O.Cl.Cl.N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 QAFZLTVOFJHYDF-UHFFFAOYSA-N 0.000 claims 5
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 5
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 2
- 229960000215 ruxolitinib Drugs 0.000 claims 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000002559 palpation Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
1. Oblik jedinične doze, naznačen time, da sadrži:
(i) spoj koji je N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamid dihidroklorid monohidrat,
(ii) mikrokristalnu celulozu, i
(iii) natrijev stearil fumarat,
pri čemu maseni omjer od N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida prema mikrokristalnoj celulozi u obliku jedinične doze iznosi 1:1,5 do 1:15, i
pri čemu maseni omjer od N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida prema natrijevom stearil fumaratu u obliku jedinične doze iznosi 50:1 do 5:1.
2. Oblik jedinične doze prema patentnom zahtjevu 1, naznačen time, da oblik jedinične doze sadrži:
(a) oko 10 mg do oko 500 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida;
(b) oko 10 mg, oko 40 mg, oko 100 mg, oko 200 mg, oko 300 mg, oko 400 mg, ili oko 500 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida; ili
(c) oko 400 mg ili oko 500 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida.
3. Oblik jedinične doze prema patentnom zahtjevu 1, naznačen time, da maseni omjer od N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida prema natrijevom stearil fumaratu u obliku jedinične doze iznosi od oko 5:1 do oko 10:1, od oko 5:1 do oko 25:1, od oko 5:1 do oko 40:1, od oko 7:1 do oko 34:1, ili od oko 8:1 do oko 34:1.
4. Oblik jedinične doze prema patentnom zahtjevu 1, naznačen time, da oblik jedinične doze sadrži:
(a) oko 12 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamid dihidroklorid monohidrata, oko 122 mg silicificirane mikrokristalne celuloze, i oko 1 mg natrijevog stearil fumarata;
(b) oko 47 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamid dihidroklorid monohidrata, oko 448 mg silicificirane mikrokristalne celuloze, i oko 5 mg natrijevog stearil fumarata;
(c) oko 117 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamid dihidroklorid monohidrata; ili
(d) oko 235 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamid dihidroklorid monohidrata, oko 357 mg silicificirane mikrokristalne celuloze, i oko 6 mg natrijevog stearil fumarata.
5. Oblik jedinične doze prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da mikrokristalna celuloza jest silicificirana mikrokristalna celuloza; i/ili maseni omjer spoja prema mikrokristalnoj celulozi iznosi oko 1:9.
6. Oblik jedinične doze prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da oblik jedinične doze jest kapsula, poželjno pritom kapsula je tvrda želatinska kapsula.
7. Oblik jedinične doze prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da je za uporabu u liječenju mijelofibroze kod pojedinca.
8. Oblik jedinične doze za uporabu prema patentnom zahtjevu 7, naznačen time, da je pojedinac prethodno primio drugačiju terapiju protiv mijelofibroze s JAK2 inhibitorom koji nije N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamid ili njegova farmaceutski prihvatljiva sol ili njegov hidrat; opcionalno,
pri čemu prethodna terapija obuhvaća primjenu INCB018424 (ruksolitinib); i/ili
pri čemu pojedinac nema odgovora na prethodnu terapiju.
9. Oblik jedinične doze za uporabu prema patentnom zahtjevu 8, naznačen time, da se oblik jedinične doze primjenjuje oralno.
10. Oblik jedinične doze za uporabu prema bilo kojem od patentnih zahtjeva 7 do 9, naznačen time, da pojedinac posjeduje visoki rizik za mijelofibrozu; pri čemu pojedinac posjeduje rizik srednjeg stupnja 2 za mijelofibrozu; pri čemu pojedinac ima veličinu slezene koja iznosi najmanje 5 cm ispod donjeg ruba rebara, kao što se mjeri palpacijom; pri čemu pojedinac ima primarnu mijelofibrozu; pri čemu pojedinac ima post-policitemijsku vera mijelofibrozu; ili pri čemu pojedinac ima post-esencijalnu trombocitemijsku mijelofibrozu.
11. Oblik jedinične doze za uporabu prema bilo kojem od patentnih zahtjeva 7 do 10, naznačen time, da se oblik jedinične doze primjenjuje dnevno; opcionalno pritom:
a) spoj se daje u dozi od oko 240 mg do oko 680 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida po danu;
b) spoj se daje u dozi od oko 300 mg do oko 500 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida po danu;
c) spoj se daje u dozi od oko 400 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida po danu; ili
d) spoj se daje u dozi od oko 500 mg N-terc-butil-3-[(5-metil-2-{[4-(2-pirolidin-1-iletoksi)fenil]amino}pirimidin-4-il)amino]benzensulfonamida po danu; i/ili
e) se pritom oblik jedinične doze daje u vremenskom periodu od najmanje jednog ciklusa, najmanje šest ciklusa, najmanje 10 ciklusa, ili najmanje 15 ciklusa od ciklusa liječenja koji traje 28 dana.
12. Oblik jedinične doze za uporabu prema bilo kojem od patentnih zahtjeva 7 do 11, naznačen time, da pojedinac je čovjek; i/ili pri čemu, nakon primjene oblika jedinične doze ljudskom pojedincu, Cmax spoja postiže se unutar oko 2 do oko 4 sata nakon davanja; i/ili eliminacijsko vrijeme poluživota spoja iznosi oko 16 do oko 34 sata; i/ili pri čemu se prosječni AUC spoja povećava više nego proporcionalno s povećavanjem doza u rasponu od oko 30 mg do oko 800 mg po danu; i/ili pri čemu akumulacija spoja iznosi oko 1,25 do oko 4,0 puta u postojanom stanju kada se spoj daje jednom dnevno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41092410P | 2010-11-07 | 2010-11-07 | |
EP11838957.6A EP2635282B1 (en) | 2010-11-07 | 2011-11-07 | Compositions for treating myelofibrosis |
PCT/US2011/059643 WO2012061833A1 (en) | 2010-11-07 | 2011-11-07 | Compositions and methods for treating myelofibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221269T1 true HRP20221269T1 (hr) | 2022-12-23 |
Family
ID=46024747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221269TT HRP20221269T1 (hr) | 2010-11-07 | 2011-11-07 | Pripravci za liječenje mijelofibroze |
Country Status (34)
Country | Link |
---|---|
US (4) | US20130252988A1 (hr) |
EP (2) | EP2635282B1 (hr) |
JP (1) | JP6133211B2 (hr) |
KR (4) | KR101940979B1 (hr) |
CN (2) | CN103282036B (hr) |
AU (2) | AU2010363329A1 (hr) |
BR (1) | BR112013011184A2 (hr) |
CA (2) | CA2816957A1 (hr) |
CL (1) | CL2013001252A1 (hr) |
CO (1) | CO6801724A2 (hr) |
DK (1) | DK2635282T3 (hr) |
DO (1) | DOP2013000097A (hr) |
EC (1) | ECSP13012658A (hr) |
ES (1) | ES2930650T3 (hr) |
HR (1) | HRP20221269T1 (hr) |
HU (1) | HUE060254T2 (hr) |
IL (1) | IL226101A (hr) |
LT (1) | LT2635282T (hr) |
MA (1) | MA34723B1 (hr) |
MX (1) | MX360246B (hr) |
MY (1) | MY161164A (hr) |
NI (1) | NI201300038A (hr) |
NZ (1) | NZ611363A (hr) |
PE (1) | PE20140389A1 (hr) |
PL (1) | PL2635282T3 (hr) |
PT (1) | PT2635282T (hr) |
RS (1) | RS63996B1 (hr) |
RU (1) | RU2616262C2 (hr) |
SG (1) | SG190134A1 (hr) |
SI (1) | SI2635282T1 (hr) |
TW (1) | TWI531389B (hr) |
UA (1) | UA114076C2 (hr) |
WO (2) | WO2012060847A1 (hr) |
ZA (1) | ZA201303423B (hr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2012060847A1 (en) * | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2013059548A1 (en) * | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
BR112015021097B1 (pt) * | 2013-03-06 | 2022-08-30 | Novartis Ag | Composição farmacêutica sólida compactada em rolo, seu uso e seu processo de fabricação |
CN104771761A (zh) * | 2015-03-19 | 2015-07-15 | 深圳国源国药有限公司 | 一种创新药用辅料硅化微晶纤维素及其制备方法 |
JP6799226B2 (ja) * | 2015-07-24 | 2020-12-16 | 公立大学法人名古屋市立大学 | 骨髄線維症の状態の診断を補助する方法、予後の予測を補助する方法、及び治療効果のモニター方法、並びにそれらの方法に用いるマーカー及び装置 |
CN105919955A (zh) * | 2016-06-13 | 2016-09-07 | 佛山市腾瑞医药科技有限公司 | 一种鲁索利替尼制剂及其应用 |
WO2019140953A1 (zh) * | 2018-01-16 | 2019-07-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
KR20210098957A (ko) * | 2018-09-25 | 2021-08-11 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
BR112021005518A2 (pt) * | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
EP3923948A4 (en) * | 2019-02-12 | 2022-11-16 | Impact Biomedicines, Inc. | CRYSTALLINE SHAPES OF A JAK2 INHIBITOR |
FR3092581A1 (fr) * | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
US11306062B2 (en) | 2019-10-29 | 2022-04-19 | Johnson Matthey Public Limited | Forms of fedratinib dihydrochloride |
US20230070369A1 (en) * | 2019-12-20 | 2023-03-09 | Intervet Inc. | Pyrazole pharmaceutical composition |
WO2021207051A1 (en) * | 2020-04-06 | 2021-10-14 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
AU2021401681A1 (en) | 2020-12-16 | 2023-06-22 | Impact Biomedicines, Inc. | Dosing of fedratinib |
KR20230148208A (ko) | 2021-02-25 | 2023-10-24 | 임팩트 바이오메디신스, 인코포레이티드 | 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도 |
WO2023044297A1 (en) | 2021-09-14 | 2023-03-23 | Impact Biomedicines, Inc. | Fedratinib for treating myeloproliferative disorders |
Family Cites Families (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003199A (en) | 1930-05-31 | 1935-05-28 | Johnson Frank James | Automatic coal stoker |
US2003149A (en) | 1931-05-22 | 1935-05-28 | Autographic Register Co | Manifolding |
US2003065A (en) | 1931-06-20 | 1935-05-28 | John R Ditmars | Composition for coating sheets, fibrous stocks, and the like |
US2004102A (en) | 1932-02-24 | 1935-06-11 | Daniel A Dickey | Hollow steel propeller construction |
US2004138A (en) | 1932-11-30 | 1935-06-11 | Byers A M Co | Method of making wrought iron pipe |
US2002165A (en) | 1933-07-08 | 1935-05-21 | Charles A Winslow | Air cleaner |
US2003187A (en) | 1933-10-02 | 1935-05-28 | Frederick H Shaw | Automobile radio device |
US2003166A (en) | 1933-10-26 | 1935-05-28 | Zancan Ottavio | Front drive for motor cars |
US2001051A (en) | 1933-12-01 | 1935-05-14 | Angelina Mariani | Tamperproof meter box with cutout control and fuse drawer for electric meters |
US2004092A (en) | 1933-12-15 | 1935-06-11 | John L Chaney | Device for indicating the temperature of liquids |
US2003060A (en) | 1934-04-02 | 1935-05-28 | Ernest L Heckert | Thermostatic controlling device |
US2667486A (en) | 1951-05-24 | 1954-01-26 | Research Corp | 2,4-diamino pteridine and derivatives |
IE38778B1 (en) | 1973-02-02 | 1978-05-24 | Ciba Geigy | New 1,2,4-benzotriazine derivatives |
AU535258B2 (en) | 1979-08-31 | 1984-03-08 | Ici Australia Limited | Benzotriazines |
DE3205638A1 (de) | 1982-02-17 | 1983-08-25 | Hoechst Ag, 6230 Frankfurt | Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
US4490289A (en) | 1982-09-16 | 1984-12-25 | Hoffmann-La Roche Inc. | Homogeneous human interleukin 2 |
US5624925A (en) | 1986-09-25 | 1997-04-29 | Sri International | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
JP2598100B2 (ja) | 1988-08-31 | 1997-04-09 | キヤノン株式会社 | 電子写真感光体 |
US5214059A (en) | 1989-07-03 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
US5665543A (en) | 1989-07-18 | 1997-09-09 | Oncogene Science, Inc. | Method of discovering chemicals capable of functioning as gene expression modulators |
US5776502A (en) | 1989-07-18 | 1998-07-07 | Oncogene Science, Inc. | Methods of transcriptionally modulating gene expression |
US5041430A (en) * | 1989-09-18 | 1991-08-20 | Du Pont Mereck Pharmaceutical Company | Oral anticoagulant/platelet inhibitor low dose formulation |
JPH03127790A (ja) | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
GB9003553D0 (en) | 1990-02-16 | 1990-04-11 | Ici Plc | Herbicidal compositions |
JP2839106B2 (ja) | 1990-02-19 | 1998-12-16 | キヤノン株式会社 | 電子写真感光体 |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
IE74711B1 (en) | 1990-07-27 | 1997-07-30 | Ici Plc | Fungicides |
GB9016800D0 (en) | 1990-07-31 | 1990-09-12 | Shell Int Research | Tetrahydropyrimidine derivatives |
DE4025891A1 (de) | 1990-08-16 | 1992-02-20 | Bayer Ag | Pyrimidyl-substituierte acrylsaeureester |
JPH05345780A (ja) | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
US5438130A (en) | 1993-01-15 | 1995-08-01 | Cambridge Neuroscience, Inc. | Fucosylated guanosine disulfates as excitatory amino acid antagonists |
JPH0741461A (ja) | 1993-05-27 | 1995-02-10 | Eisai Co Ltd | スルホン酸エステル誘導体 |
JPH0782183A (ja) | 1993-09-09 | 1995-03-28 | Canon Inc | 液晶中間体化合物、液晶性化合物、高分子液晶化合物、高分子液晶共重合体化合物、それらの組成物、液晶素子および記録装置 |
DE4338704A1 (de) | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
US5530000A (en) | 1993-12-22 | 1996-06-25 | Ortho Pharmaceutical Corporation | Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
DE19502912A1 (de) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
US6326487B1 (en) | 1995-06-05 | 2001-12-04 | Aventis Pharma Deutschland Gmbh | 3 modified oligonucleotide derivatives |
WO1997009315A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
KR19990076876A (ko) | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
JPH09274290A (ja) | 1996-02-07 | 1997-10-21 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料用の現像液および処理方法 |
ATE305781T1 (de) | 1996-02-23 | 2005-10-15 | Lilly Co Eli | Non-peptidische vasopressin via antagonisten |
DE59707681D1 (de) | 1996-10-28 | 2002-08-14 | Rolic Ag Zug | Vernetzbare, photoaktive Silanderivate |
ATE348155T1 (de) | 1996-11-20 | 2007-01-15 | Introgen Therapeutics Inc | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
JP3734903B2 (ja) | 1996-11-21 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
JPH10153838A (ja) | 1996-11-22 | 1998-06-09 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JP3720931B2 (ja) | 1996-11-26 | 2005-11-30 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料の処理方法 |
CN1240010A (zh) | 1996-12-04 | 1999-12-29 | 金伯利-克拉克环球有限公司 | 湿强度纸的制备方法 |
US5935383A (en) | 1996-12-04 | 1999-08-10 | Kimberly-Clark Worldwide, Inc. | Method for improved wet strength paper |
ATE236890T1 (de) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
JPH10207019A (ja) | 1997-01-22 | 1998-08-07 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JPH10213820A (ja) | 1997-01-31 | 1998-08-11 | Canon Inc | 液晶素子及び液晶装置 |
DE59807348D1 (de) | 1997-02-05 | 2003-04-10 | Rolic Ag Zug | Photovernetzbare Silanderivate |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
JPH10260512A (ja) | 1997-03-19 | 1998-09-29 | Fuji Photo Film Co Ltd | ハロゲン化銀感光材料の処理方法 |
JPH10310583A (ja) | 1997-05-09 | 1998-11-24 | Mitsubishi Chem Corp | ピリドンアゾ系化合物、感熱転写用色素およびそれを使用した感熱転写材料 |
US6070126A (en) | 1997-06-13 | 2000-05-30 | William J. Kokolus | Immunobiologically-active linear peptides and method of identification |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US6635626B1 (en) | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6432963B1 (en) | 1997-12-15 | 2002-08-13 | Yamanouchi Pharmaceutical Co., Ltd. | Pyrimidine-5-carboxamide derivatives |
BR9813835A (pt) | 1997-12-22 | 2000-10-10 | Du Pont Pharm Co | Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica |
JP2002503662A (ja) | 1998-02-17 | 2002-02-05 | テュラリク インコーポレイテッド | 抗ウイルス性ピリミジン誘導体 |
ES2361146T3 (es) | 1998-03-27 | 2011-06-14 | Janssen Pharmaceutica Nv | Derivados de la piramidina inhibitatoria de vih. |
SK287996B6 (sk) | 1998-03-27 | 2012-09-03 | Janssen Pharmaceutica N. V. | Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound |
US6685938B1 (en) | 1998-05-29 | 2004-02-03 | The Scripps Research Institute | Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases |
DE19830181C1 (de) | 1998-07-06 | 1999-09-30 | Inter Control Koehler Hermann | Mehrpolige elektrische Steckverbindung |
US6136971A (en) | 1998-07-17 | 2000-10-24 | Roche Colorado Corporation | Preparation of sulfonamides |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
DK1117659T3 (da) | 1998-09-29 | 2004-03-22 | Wyeth Corp | Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser |
AU6159499A (en) | 1998-09-29 | 2000-04-17 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
WO2000039102A1 (en) | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
MXPA01007957A (es) | 1999-02-04 | 2002-07-30 | Millennium Pharm Inc | Receptor helicoidal acoplado a la proteina-g que une compuestos y metodos para el uso del mismo. |
IL144910A0 (en) | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
HUP0200816A3 (en) | 1999-04-21 | 2003-06-30 | Wyeth Holdings Corp Madison | Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases, process for their preparation and pharmaceutical compositions containing them |
WO2000071536A1 (en) | 1999-05-20 | 2000-11-30 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
US6710221B1 (en) | 1999-06-15 | 2004-03-23 | Kimberly-Clark Worldwide, Inc. | Absorbent articles incorporating color change graphics |
CA2377771A1 (en) | 1999-07-01 | 2001-01-11 | Ajinomoto Co., Inc. | Heterocyclic compounds and medical use thereof |
WO2001007027A2 (en) | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
AU6016000A (en) | 1999-07-23 | 2001-02-13 | Shionogi & Co., Ltd. | Tricyclic compounds and drug compositions containing the same |
AU763976B2 (en) | 1999-07-23 | 2003-08-07 | Shionogi & Co., Ltd. | Th2 differentiation inhibitors |
HUP0203162A3 (en) | 1999-08-12 | 2006-07-28 | Wyeth Holdings Corp Madison | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
US6093838A (en) | 1999-08-16 | 2000-07-25 | Allergan Sales, Inc. | Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
US6127382A (en) | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
ES2250186T3 (es) | 1999-09-10 | 2006-04-16 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
AU7683500A (en) | 1999-10-12 | 2001-04-23 | Takeda Chemical Industries Ltd. | Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof |
WO2001032628A1 (en) | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
GB9929988D0 (en) | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
CN1262541C (zh) | 1999-12-29 | 2006-07-05 | 惠氏公司 | 三环蛋白激酶抑制剂 |
US6638929B2 (en) | 1999-12-29 | 2003-10-28 | Wyeth | Tricyclic protein kinase inhibitors |
WO2001055116A2 (en) | 2000-01-28 | 2001-08-02 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
US6153752A (en) | 2000-01-28 | 2000-11-28 | Creanova, Inc. | Process for preparing heterocycles |
US20020165244A1 (en) | 2000-01-31 | 2002-11-07 | Yuhong Zhou | Mucin synthesis inhibitors |
CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
AU2001238469C1 (en) | 2000-02-18 | 2006-08-24 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
HUP0300029A2 (en) | 2000-02-25 | 2003-05-28 | Hoffmann La Roche | Adenosine receptor modulators, pharmaceutical compositions containing them and their use |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
WO2001064674A1 (en) | 2000-03-01 | 2001-09-07 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
AU2001245401A1 (en) | 2000-03-01 | 2001-09-12 | Sumitomo Pharmaceuticals Company, Limited | Hydrazones and analogs as cholesterol lowering agents |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
JP2001247411A (ja) | 2000-03-09 | 2001-09-11 | Tomono Agrica Co Ltd | 有害生物防除剤 |
CA2402742C (en) | 2000-03-13 | 2009-05-12 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
US6613917B1 (en) | 2000-03-23 | 2003-09-02 | Allergan, Inc. | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
US6608048B2 (en) | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
AR028261A1 (es) | 2000-03-28 | 2003-04-30 | Wyeth Corp | Inhibidores triciclicos de la proteina quinasa |
MXPA02009763A (es) | 2000-04-04 | 2003-03-27 | Shionogi & Co | Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa. |
WO2001076582A1 (fr) | 2000-04-05 | 2001-10-18 | Shionogi & Co., Ltd. | Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci |
US6471968B1 (en) | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
DE10024622A1 (de) | 2000-05-18 | 2001-11-22 | Piesteritz Stickstoff | N-(2-Pyrimidinyl)(thio)phosphorsäuretriamide, Verfahren zu ihrer Herstellung und deren Verwendung als Mittel zur Regulierung bzw. Hemmung der enzymatischen Harnstoff-Hydrolyse |
US6875483B2 (en) | 2000-07-06 | 2005-04-05 | Fuji Photo Film Co., Ltd. | Liquid crystal composition comprising liquid crystal molecules and alignment promoter |
US6489328B2 (en) | 2000-08-11 | 2002-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
DE60120193T2 (de) | 2000-09-15 | 2007-03-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinasehemmer |
AU2002213467A8 (en) | 2000-10-11 | 2009-07-30 | Chemocentryx Inc | Modulation of ccr4 function |
JP2004517059A (ja) | 2000-11-02 | 2004-06-10 | アストラゼネカ アクチボラグ | 抗腫瘍剤用の4−置換キノリン類 |
EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
JP2004517074A (ja) | 2000-11-20 | 2004-06-10 | ファルマシア・コーポレーション | 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類 |
US20070026433A1 (en) * | 2001-03-09 | 2007-02-01 | Hildebrand William H | Epitope testing using soluble HLA |
WO2002053160A1 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating glaucoma ivb |
EP1359911A2 (en) | 2000-12-29 | 2003-11-12 | Alteon, Inc. | Method for treating fibrotic diseases or other indications ivc |
JP2002221770A (ja) | 2001-01-24 | 2002-08-09 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料およびその処理方法 |
WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
CZ20032258A3 (cs) | 2001-02-23 | 2004-01-14 | Merck & Co., Inc. | N-substituované nearylové heterocyklické sloučeniny |
JP2004525139A (ja) | 2001-03-23 | 2004-08-19 | 中外製薬株式会社 | Flt−1リガンド、および血管形成により調節可能な疾患の治療におけるそれらの使用 |
JP2004535381A (ja) | 2001-04-13 | 2004-11-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | c−JunN末端キナーゼ(JNK)および他のプロテインキナーゼのインヒビター |
WO2002090347A1 (en) | 2001-04-30 | 2002-11-14 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds |
MXPA03010269A (es) | 2001-05-11 | 2004-05-05 | Vertex Pharma | Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38. |
WO2002094766A1 (fr) | 2001-05-18 | 2002-11-28 | Nihon Nohyaku Co., Ltd. | Derive de phtalamide, insecticide agricole et horticole et son utilisation |
JP2004534046A (ja) | 2001-05-28 | 2004-11-11 | アベンティス・ファーマ・ソシエテ・アノニム | 化学誘導体および抗テロメラーゼ剤としてのその使用 |
EP1392662B1 (de) | 2001-05-29 | 2009-01-07 | Bayer Schering Pharma Aktiengesellschaft | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel |
US7514098B2 (en) | 2001-05-30 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Use of targeted cross-linked nanoparticles for in vivo gene delivery |
JP4523271B2 (ja) | 2001-06-01 | 2010-08-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール化合物 |
WO2003004492A1 (en) | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
US6861529B2 (en) | 2001-07-06 | 2005-03-01 | Pfizer Inc | Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
MXPA04002397A (es) | 2001-09-14 | 2004-12-02 | Methylgene Inc | Inhibidores de histona deacetilasa. |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
DE10150614A1 (de) | 2001-10-12 | 2003-04-30 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen |
DE10150615A1 (de) | 2001-10-12 | 2003-04-30 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte |
DE10150610A1 (de) | 2001-10-12 | 2003-04-30 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Amidbasen |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
ATE375331T1 (de) | 2001-11-01 | 2007-10-15 | Janssen Pharmaceutica Nv | Amidderivate als inhibitoren der glycogensynthasekinase-3-beta |
AU2002363176B2 (en) | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors) |
AR037438A1 (es) | 2001-11-27 | 2004-11-10 | Wyeth Corp | 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
WO2003045921A1 (en) | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003057165A2 (en) | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
US20030166932A1 (en) | 2002-01-04 | 2003-09-04 | Beard Richard L. | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CA2475141A1 (en) | 2002-02-05 | 2003-08-14 | Wyeth | Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids |
US7459455B2 (en) | 2002-02-08 | 2008-12-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
MXPA04008458A (es) | 2002-03-01 | 2004-12-06 | Smithkline Beecham Corp | Diamino pirimidinas y su uso como inhibidores de angiogenesis. |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
MXPA04011849A (es) | 2002-07-02 | 2005-03-31 | Kimberly Clark Co | Composiciones adhesivas elastomericas y laminados. |
US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
CN100491374C (zh) | 2002-08-02 | 2009-05-27 | Ab科学公司 | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 |
WO2004016597A2 (en) | 2002-08-14 | 2004-02-26 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
DE10240261A1 (de) | 2002-08-31 | 2004-03-11 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen |
DE10240262A1 (de) | 2002-08-31 | 2004-03-11 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen |
CA2500727A1 (en) | 2002-10-03 | 2004-04-15 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US20050282814A1 (en) | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
AU2003279795A1 (en) | 2002-10-04 | 2004-05-04 | Caritas St.Elisabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
AU2003301662A1 (en) | 2002-10-21 | 2004-05-13 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
DE10250708A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
AU2003295396B2 (en) | 2002-11-04 | 2009-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as JAK inhibitors |
US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
BR0316386A (pt) | 2002-12-06 | 2005-09-27 | Warner Lambert Co | Benzoxazin-3-onas e seus derivados como inibidores de p13k |
WO2004054186A1 (ja) | 2002-12-12 | 2004-06-24 | Fujitsu Limited | データ中継装置、連想メモリデバイス、および連想メモリデバイス利用情報検索方法 |
JP2006518333A (ja) | 2002-12-20 | 2006-08-10 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
AU2003299600A1 (en) | 2002-12-20 | 2004-07-29 | Pharmacia Corpration | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
JP2006512387A (ja) | 2002-12-24 | 2006-04-13 | アストラゼネカ アクチボラグ | 化合物 |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
EP1597242B1 (en) | 2003-02-07 | 2008-07-23 | Janssen Pharmaceutica N.V. | Hiv inhibiting 1,2,4-triazines |
MXPA05008364A (es) | 2003-02-07 | 2005-11-04 | Janssen Pharmaceutica Nv | Derivados de pirimidina para la prevencion de una infeccion por vih. |
US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CA2559670A1 (en) | 2003-04-14 | 2004-10-28 | Gabor Pragai | Stable amlodipine maleate formulations |
US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
US20040214914A1 (en) | 2003-04-24 | 2004-10-28 | Ocular Sciences, Inc. | Hydrogel contact lenses and package systems and production methods for same |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
SI1660458T1 (sl) | 2003-08-15 | 2012-05-31 | Novartis Ag | pirimidindiamini uporabni pri zdravljenju neoplastičnih bolezni vnetnih motenj in motenj imunskega sistema |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
CA2538413A1 (en) | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
RU2006139258A (ru) | 2004-04-08 | 2008-05-20 | Таргеджен, Инк. (US) | Бензотриазиновые ингибиторы киназ |
AU2005276974B2 (en) | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
US7210697B2 (en) | 2004-12-16 | 2007-05-01 | Tricam International, Inc. | Convertible handle |
AU2005322855B2 (en) | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
GT200600008A (es) * | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN101155799A (zh) | 2005-03-16 | 2008-04-02 | 塔格根公司 | 嘧啶化合物和使用方法 |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
EP1904457B1 (en) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20060292203A1 (en) | 2005-06-08 | 2006-12-28 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
WO2006137658A1 (en) | 2005-06-20 | 2006-12-28 | Dongbu Hitek Co., Ltd. | New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same |
RS20070511A (en) * | 2005-06-29 | 2009-01-22 | Panacea Biotec Ltd., | Modified release pharmaceutical compositions and processes thereof |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
US20070072682A1 (en) | 2005-09-29 | 2007-03-29 | Crawford James T Iii | Head to head electronic poker game assembly and method of operation |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
UA109411C2 (uk) * | 2005-11-01 | 2015-08-25 | N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки | |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20070161645A1 (en) | 2005-11-02 | 2007-07-12 | Targegen, Inc. | Thiazole inhibitors targeting resistant kinase mutations |
CA2628474A1 (en) | 2005-11-03 | 2007-05-10 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
EP1954256A2 (en) | 2005-11-09 | 2008-08-13 | Torrent Pharmaceuticals Ltd | Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent |
WO2007058627A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Oxygen linked pyrimidine derivatives |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
JP2009525337A (ja) * | 2006-01-30 | 2009-07-09 | エクセリクシス, インク. | Jak−2調節因子としての4−アリール−2−アミノ−ピリミジン類又は4−アリール−2−アミノアルキル−ピリミジン類と使用方法 |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
MX349787B (es) * | 2006-04-04 | 2017-08-11 | Kg Acquisition Llc | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. |
WO2007127366A2 (en) | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
US20070264330A1 (en) * | 2006-05-15 | 2007-11-15 | Bo Ragnar-Tolf | Pharmaceutical formulations of pimavanserin |
US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
US20080021013A1 (en) | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
JP2009544592A (ja) | 2006-07-21 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | Jakキナーゼ阻害剤としての2,4−ジ(アリールアミノ)−ピリミジン−5−カルボキサミド化合物 |
WO2008057233A2 (en) * | 2006-10-25 | 2008-05-15 | The Regents Of The University Of California | Models of erythropoiesis |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
DE102007034947B4 (de) * | 2007-07-26 | 2009-06-18 | Siemens Ag | Vorrichtung zum Entladen eines Stapels von auf ihren Schmalseiten stehenden flachen Gegenständen |
JP2010536371A (ja) * | 2007-08-21 | 2010-12-02 | ノダリティ,インコーポレイテッド | 診断方法、予後および治療方法 |
WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
US20100310563A1 (en) * | 2007-11-30 | 2010-12-09 | Bumm Thomas G P | Methods for treating induced cellular proliferative disorders |
WO2010008995A2 (en) * | 2008-07-14 | 2010-01-21 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
BRPI0917575A2 (pt) | 2008-08-05 | 2019-09-24 | Targegen Inc | métodos de tratamento de talassemia |
US8987243B2 (en) | 2008-12-11 | 2015-03-24 | Cti Biopharma Corp. | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt |
PL2229938T3 (pl) | 2009-03-13 | 2012-09-28 | Sanovel Ilac Sanayi Ve Ticaret As | Kompozycje ezetymibu |
US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
US20120190806A1 (en) | 2009-07-31 | 2012-07-26 | Basf Se | Phosphine Borane Compounds Comprising Imidazol Groups And Method For Producing Phosphine Borane Compounds Comprising Imidazol Groups |
WO2011025685A1 (en) | 2009-08-24 | 2011-03-03 | Merck Sharp & Dohme Corp. | Jak inhibition blocks rna interference associated toxicities |
WO2012060847A1 (en) * | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2013013195A1 (en) | 2011-07-21 | 2013-01-24 | Sanofi | Compositions and methods for treating polycythemia vera and essential thrombocythemia |
WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
-
2010
- 2010-11-10 WO PCT/US2010/056280 patent/WO2012060847A1/en active Application Filing
- 2010-11-10 AU AU2010363329A patent/AU2010363329A1/en not_active Abandoned
- 2010-11-10 CA CA2816957A patent/CA2816957A1/en not_active Abandoned
-
2011
- 2011-07-11 UA UAA201307185A patent/UA114076C2/uk unknown
- 2011-11-07 RU RU2013126121A patent/RU2616262C2/ru active
- 2011-11-07 PT PT118389576T patent/PT2635282T/pt unknown
- 2011-11-07 EP EP11838957.6A patent/EP2635282B1/en active Active
- 2011-11-07 NZ NZ611363A patent/NZ611363A/en unknown
- 2011-11-07 BR BR112013011184A patent/BR112013011184A2/pt not_active Application Discontinuation
- 2011-11-07 ES ES11838957T patent/ES2930650T3/es active Active
- 2011-11-07 KR KR1020137014479A patent/KR101940979B1/ko active Protection Beyond IP Right Term
- 2011-11-07 KR KR1020247006181A patent/KR20240029118A/ko active Application Filing
- 2011-11-07 MX MX2013005020A patent/MX360246B/es active IP Right Grant
- 2011-11-07 KR KR1020187031287A patent/KR102131241B1/ko active Protection Beyond IP Right Term
- 2011-11-07 CN CN201180064283.0A patent/CN103282036B/zh active Active
- 2011-11-07 CN CN201711395025.6A patent/CN108125923A/zh active Pending
- 2011-11-07 SG SG2013034111A patent/SG190134A1/en unknown
- 2011-11-07 TW TW100140569A patent/TWI531389B/zh active
- 2011-11-07 JP JP2013537919A patent/JP6133211B2/ja active Active
- 2011-11-07 RS RS20221063A patent/RS63996B1/sr unknown
- 2011-11-07 WO PCT/US2011/059643 patent/WO2012061833A1/en active Application Filing
- 2011-11-07 DK DK11838957.6T patent/DK2635282T3/da active
- 2011-11-07 MY MYPI2013001613A patent/MY161164A/en unknown
- 2011-11-07 SI SI201132071T patent/SI2635282T1/sl unknown
- 2011-11-07 AU AU2011323108A patent/AU2011323108B2/en active Active
- 2011-11-07 PL PL11838957.6T patent/PL2635282T3/pl unknown
- 2011-11-07 KR KR1020207019018A patent/KR20200083676A/ko not_active IP Right Cessation
- 2011-11-07 CA CA2816710A patent/CA2816710A1/en not_active Abandoned
- 2011-11-07 EP EP22197669.9A patent/EP4159216A1/en active Pending
- 2011-11-07 PE PE2013000959A patent/PE20140389A1/es not_active Application Discontinuation
- 2011-11-07 LT LTEPPCT/US2011/059643T patent/LT2635282T/lt unknown
- 2011-11-07 HU HUE11838957A patent/HUE060254T2/hu unknown
- 2011-11-07 HR HRP20221269TT patent/HRP20221269T1/hr unknown
-
2013
- 2013-05-01 IL IL226101A patent/IL226101A/en active IP Right Grant
- 2013-05-03 DO DO2013000097A patent/DOP2013000097A/es unknown
- 2013-05-06 US US13/888,073 patent/US20130252988A1/en not_active Abandoned
- 2013-05-06 US US13/888,096 patent/US10391094B2/en active Active
- 2013-05-06 CL CL2013001252A patent/CL2013001252A1/es unknown
- 2013-05-06 NI NI201300038A patent/NI201300038A/es unknown
- 2013-05-10 ZA ZA2013/03423A patent/ZA201303423B/en unknown
- 2013-06-04 EC ECSP13012658 patent/ECSP13012658A/es unknown
- 2013-06-05 MA MA35978A patent/MA34723B1/fr unknown
- 2013-06-07 CO CO13138069A patent/CO6801724A2/es not_active Application Discontinuation
-
2019
- 2019-08-23 US US16/549,043 patent/US20190381041A1/en active Pending
-
2021
- 2021-04-01 US US17/220,073 patent/US20210244735A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
HRP20192065T1 (hr) | Čvrsti oblici doziranja palbocikliba | |
KR20110046554A (ko) | 엔타카폰 또는 이의 염의 서방형 약학 조성물 | |
HRP20121072T1 (hr) | Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja | |
HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
HRP20100276T1 (hr) | Gaboksadol za liječenje depresije i drugih afektivnih poremećaja | |
RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
SI3079671T1 (en) | Oral disintegration solid dosage form containing an esterol component | |
HRP20121033T1 (hr) | Praškasta formulacija za valganciklovir | |
JP2013541595A5 (hr) | ||
RU2006135124A (ru) | Фармацевтические композиции толперизона контролируемого высвобождения, предназначенные для перорального введения | |
US8968778B2 (en) | Threo-DOPS controlled release formulation | |
TW201609091A (zh) | 用於口服投藥之包含依澤替米貝(ezetimibe)及羅舒伐他汀(rosuvastatin)的複合調配物 | |
CN104411301B (zh) | 适于改善运动障碍治疗的口服药物配方 | |
JP2017531033A5 (hr) | ||
HRP20141234T1 (hr) | Tapentadol za tretiranje boli od artritisa | |
RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
JP2020530489A (ja) | リモノイド化合物とビグアニド化合物を含有する組み合わせ製品 | |
JP2019529570A5 (hr) | ||
RU2009102443A (ru) | Фармацевтический препарат для контрацепции и для предотвращения риска врожденных пороков развития | |
EP1868597A1 (en) | Therapeutic use of nefopam and analogues thereof | |
RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
BRPI0609779A2 (pt) | composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide | |
KR20110046555A (ko) | 레보도파, 카비도파 및 엔타카폰 또는 이의 염을 포함하는 단일 단위 경구 투여 약학 조성물 | |
JP2012041314A5 (hr) |